Mesa Laboratories (NASDAQ:MLAB) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $94.55 and traded as high as $101.10. Mesa Laboratories shares last traded at $101.04, with a volume of 90,861 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $94.00.

Mesa Laboratories Stock Performance

The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The firm has a 50-day simple moving average of $100.46 and a two-hundred day simple moving average of $94.55. The company has a market capitalization of $565.82 million, a price-to-earnings ratio of 84.20 and a beta of 0.93.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25). The firm had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a net margin of 2.69% and a return on equity of 20.96%. During the same quarter in the prior year, the firm earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a $0.16 dividend. The ex-dividend date is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a yield of 0.6%. Mesa Laboratories’s dividend payout ratio is currently 53.33%.

Insider Activity at Mesa Laboratories

In other Mesa Laboratories news, CAO Lyndsey Elizabeth Crennen sold 442 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares in the company, valued at $180,790. The trade was a 17.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the sale, the senior vice president owned 6,377 shares of the company’s stock, valued at $570,741.50. This trade represents a 28.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 8,277 shares of company stock valued at $770,122. 2.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Mesa Laboratories during the fourth quarter worth $27,000. Kestra Advisory Services LLC acquired a new position in Mesa Laboratories during the fourth quarter worth $55,000. BNP Paribas Financial Markets raised its holdings in Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 243 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Mesa Laboratories by 432.9% during the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 684 shares in the last quarter. Institutional investors own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.